These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36753780)

  • 1. PD-1 blockade augments CD8
    Nakasuka T; Ohashi K; Nishii K; Hirabae A; Okawa S; Tomonobu N; Takada K; Ando C; Watanabe H; Makimoto G; Ninomiya K; Fujii M; Kubo T; Ichihara E; Hotta K; Tabata M; Kumon H; Maeda Y; Kiura K
    Lung Cancer; 2023 Apr; 178():1-10. PubMed ID: 36753780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising Gene Therapy Using an Adenovirus Vector Carrying REIC/Dkk-3 Gene for the Treatment of Biliary Cancer.
    Tanaka E; Uchida D; Shiraha H; Kato H; Ohyama A; Iwamuro M; Watanabe M; Kumon H; Okada H
    Curr Gene Ther; 2020; 20(1):64-70. PubMed ID: 32148193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf-3 expressing adenoviral vector for hepatocellular carcinoma.
    Sawahara H; Shiraha H; Uchida D; Kato H; Kato R; Oyama A; Nagahara T; Iwamuro M; Horiguchi S; Tsutsumi K; Mandai M; Mimura T; Wada N; Takeuchi Y; Kuwaki K; Onishi H; Nakamura S; Watanabe M; Sakaguchi M; Takaki A; Nouso K; Yagi T; Nasu Y; Kumon H; Okada H
    J Gastroenterol Hepatol; 2017 Oct; 32(10):1769-1777. PubMed ID: 28168749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer.
    Nishii K; Ohashi K; Tomida S; Nakasuka T; Hirabae A; Okawa S; Nishimura J; Higo H; Watanabe H; Kano H; Ando C; Makimoto G; Ninomiya K; Kato Y; Kubo T; Ichihara E; Hotta K; Tabata M; Toyooka S; Udono H; Maeda Y; Kiura K
    Cancer Immunol Res; 2022 Sep; 10(9):1111-1126. PubMed ID: 35802887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-cancer effects of REIC/Dkk-3-encoding adenoviral vector for the treatment of non-small cell lung cancer.
    Shien K; Tanaka N; Watanabe M; Soh J; Sakaguchi M; Matsuo K; Yamamoto H; Furukawa M; Asano H; Tsukuda K; Nasu Y; Huh NH; Miyoshi S; Kumon H; Toyooka S
    PLoS One; 2014; 9(2):e87900. PubMed ID: 24498395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR mutations induce the suppression of CD8
    Huang H; Zhu X; Yu Y; Li Z; Yang Y; Xia L; Lu S
    J Transl Med; 2024 Jul; 22(1):653. PubMed ID: 39004699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies.
    Suzawa K; Shien K; Peng H; Sakaguchi M; Watanabe M; Hashida S; Maki Y; Yamamoto H; Tomida S; Soh J; Asano H; Tsukuda K; Nasu Y; Kumon H; Miyoshi S; Toyooka S
    Anticancer Res; 2017 Jan; 37(1):301-307. PubMed ID: 28011506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector.
    Watanabe M; Sakaguchi M; Kinoshita R; Kaku H; Ariyoshi Y; Ueki H; Tanimoto R; Ebara S; Ochiai K; Futami J; Li SA; Huang P; Nasu Y; Huh NH; Kumon H
    Oncol Rep; 2014 Mar; 31(3):1089-95. PubMed ID: 24398705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 12. A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy.
    Oka T; Kurozumi K; Shimazu Y; Ichikawa T; Ishida J; Otani Y; Shimizu T; Tomita Y; Sakaguchi M; Watanabe M; Nasu Y; Kumon H; Date I
    Sci Rep; 2016 Sep; 6():33319. PubMed ID: 27625116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer.
    Sawahara H; Shiraha H; Uchida D; Kato H; Nagahara T; Iwamuro M; Kataoka J; Horiguchi S; Watanabe M; Sakaguchi M; Takaki A; Nouso K; Nasu Y; Kumon H; Okada H
    Cancer Gene Ther; 2016 Aug; 23(8):278-83. PubMed ID: 27468808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent High PD-L1 Expression and CD8
    Shimoda Y; Shibaki R; Yoshida T; Murakami S; Shirasawa M; Torasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y; Motoi N
    Clin Lung Cancer; 2022 Sep; 23(6):477-486. PubMed ID: 35644780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis.
    Hattori Y; Kurozumi K; Otani Y; Uneda A; Tsuboi N; Makino K; Hirano S; Fujii K; Tomita Y; Oka T; Matsumoto Y; Shimazu Y; Michiue H; Kumon H; Date I
    PLoS One; 2022; 17(8):e0273242. PubMed ID: 36006934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer.
    Qiao M; Zhou F; Liu X; Jiang T; Wang H; Jia Y; Li X; Zhao C; Cheng L; Chen X; Ren S; Liu H; Zhou C
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of EGFR improves responsiveness to PD-1 blockade in
    Sugiyama E; Togashi Y; Takeuchi Y; Shinya S; Tada Y; Kataoka K; Tane K; Sato E; Ishii G; Goto K; Shintani Y; Okumura M; Tsuboi M; Nishikawa H
    Sci Immunol; 2020 Jan; 5(43):. PubMed ID: 32005679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of CD8 T cell apoptosis and EGFR mutation in non-small lung cancer patients.
    Zhao C; Su C; Li X; Zhou C
    Thorac Cancer; 2020 Aug; 11(8):2130-2136. PubMed ID: 32500560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.